drugset / Trial / NCT01526317

A Phase 1 Clinical Trial to Investigate Pharmacokinetics and Drug Interaction of Crestor and Glucodown OR SR in Healthy Volunteers

NCT01526317 ↗

Phase 1 Completed 36 enrolled Yuhan Corporation
RandomizedCrossoverOpen-label

Summary

This clinical trial is designed to compare the pharmacokinetic characteristics of combination and separate administration of Crestor(Rosuvastatin) and Glucodown(Metformin SR). Also investigate drug interaction between separate and combination administration. Total number of subjects is 36. 6 group(6 for 1 group), 3 period, consecutive 5 day administration, 10 days washout after 5th day of administration. All subjects take Crestor alone, Glucodown alone, Crestor+Glucodown combination during 3 each period.

Timeline

Start
2011-12
Primary completion
2012-05
Completion
2012-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 750 mg —
Subject Rosuvastatin Small molecule 10 mg —

Indications

No indication recorded.